Erratum to: Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study

**Hartmut Pollmann · Robert Klamroth ·
Natascha Vidovic · Alexander Y. Kriukov ·
Joshua Epstein · Ingo Abraham · Gerald Spotts ·
Johannes Oldenburg**

Published online: 1 May 2013
© Springer-Verlag Berlin Heidelberg 2013

**Erratum to: Ann Hematol (2013) 92: 689-698
DOI 10.1007/s00277-013-1678-4**

Conflict of interest was inadvertently claimed to be non-existing.

Conflict of interest Hartmut POLLMANN received research funding from Baxter. Robert KLAMROTH received research funding and speaker honoraria from Baxter. Johannes OLDENBURG received reimbursement of attending symposia/congresses and/or honoraria for consulting, and/or funds for research from Baxter, Bayer, BiogenIdec, Biotest, CSL-Behring, Grifols, Inspiration, NovoNordisk, Octapharma, Swedish Orphan Biovitrum and Wyeth/Pfizer. Natascha VIDOVIC declares no conflict of interest. Alexander Y. KRIUKOV, Gerald SPOTTS, Joshua EPSTEIN and Ingo ABRAHAM are employees of Baxter.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00277-013-1678-4>.

H. Pollmann (✉)
Ambulanzzentrum an der Raphaelsklinik, Institut für
Thrombophilie und Hämostaseologie, Loerstraße 19,
48143 Münster, Germany
e-mail: ith@haemophilie-zentrum.de

R. Klamroth
Klinik für Innere Medizin, Hämostasiezentrum,
Vivantes-Klinikum in Friedrichshagen, Berlin, Germany

N. Vidovic · J. Oldenburg
Institute of Experimental Haematology and Transfusion Medicine,
University Clinic Bonn, Bonn, Germany

A. Y. Kriukov
Baxter Healthcare Corporation, Round Lake, IL, USA

J. Epstein · G. Spotts
Baxter Healthcare Corporation, Westlake Village, CA, USA

I. Abraham
Baxter Deutschland GmbH, Unterschleißheim, Germany